Skip to main content
. 2021 Feb 17;11:4030. doi: 10.1038/s41598-021-83612-3

Figure 5.

Figure 5

Response of dissociated tumour cells. Ability of pembrolizumab (anti-PD-1; 1.0 μg/ml) to modify IFNγ (A,D) or IL-10 (B,E) secretion by dissociated tumour cells from lung (AC) or colon (DF) tumours stimulated with allogeneic mature dendritic cells. (A,B,D,E) indicate responses of individual tumours (each colour represents an individual tumour), (C,F) indicate the percentage change in response in the presence of pembrolizumab relative to isotype control (mean + SEM; n = 11 [lung]; n = 4 [colon]). The impact of pembrolizumab was statistically significant compared to isotype control (^one sample Wilcoxon test). The difference between IFNγ and IL-10 was statistically significant (Mann–Whitney U test).